Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Mar;41(3):641–646. doi: 10.1128/aac.41.3.641

Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase.

D B Mendel 1, T Cihlar 1, K Moon 1, M S Chen 1
PMCID: PMC163765  PMID: 9056007

Abstract

Cidofovir (HPMPC) [1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]-cytosine] is an acyclic nucleotide analog with potent and selective activity against herpesviruses. The prodrug, cyclic HPMPC (cHPMPC) [1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl) methyl]cytosine], has antiviral activity similar to that of the parent compound but exhibits reduced toxicity in animal models. cHPMPC is converted to cidofovir by a cellular cyclic CMP phosphodiesterase (EC 3.1.4.37) which hydrolyzes a variety of substrates, including adenosine 3',5'-cyclic monophosphate (cAMP) and cytidine 3',5'-cyclic monophosphate (cCMP). The K(m) and Vmax values for hydrolysis of cHPMPC by cCMP phosphodiesterase purified from human liver are 250 microM and 0.66 nmol.min-1.unit-1, respectively. These values are similar to the K(m) and Vmax values for cAMP (23 microM and 1.16 nmol.min-1.unit-1, respectively) and cCMP (75 microM and 2.32 nmol.min-1.unit of enzyme-1, respectively). The catalytic efficiency (Vmax/K(m) ratio) of this enzyme for the cHPMPC substrate is only 10- to 20-fold lower than those for the natural cyclic nucleotides, indicating that cHPMPC is a viable intracellular substrate for the human enzyme. Kinetic analysis indicates that cHPMPC, cAMP, and cCMP are competitive with respect to each other and that they are hydrolyzed by the same enzyme. cHPMPC is hydrolyzed to cidofovir in all primary human cell systems tested, including those derived from target organs that might be infected in patients with human cytomegalovirus (HCMV) disease. Importantly, hydrolysis of cHPMPC is not diminished in cells infected with HCMV.

Full Text

The Full Text of this article is available as a PDF (180.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aduma P., Connelly M. C., Srinivas R. V., Fridland A. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates. Mol Pharmacol. 1995 Apr;47(4):816–822. [PubMed] [Google Scholar]
  2. Bischofberger N., Hitchcock M. J., Chen M. S., Barkhimer D. B., Cundy K. C., Kent K. M., Lacy S. A., Lee W. A., Li Z. H., Mendel D. B. 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob Agents Chemother. 1994 Oct;38(10):2387–2391. doi: 10.1128/aac.38.10.2387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bronson J. J., Ghazzouli I., Hitchcock M. J., Webb R. R., 2nd, Martin J. C. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. J Med Chem. 1989 Jul;32(7):1457–1463. doi: 10.1021/jm00127a010. [DOI] [PubMed] [Google Scholar]
  4. Cech S. Y., Ignarro L. J. Cytidine 3',5'-monophosphate (cyclic CMP) formation by homogenates of mouse liver. Biochem Biophys Res Commun. 1978 Jan 13;80(1):119–125. doi: 10.1016/0006-291x(78)91112-9. [DOI] [PubMed] [Google Scholar]
  5. Cech S. Y., Ignarro L. J. Cytidine 3',5'-monophosphate (cyclic CMP) formation in mammalian tissues. Science. 1977 Dec 9;198(4321):1063–1065. doi: 10.1126/science.22127. [DOI] [PubMed] [Google Scholar]
  6. Chen M. S., Suttmann R. T., Wu J. C., Prisbe E. J. Metabolism of 4'-azidothymidine. A compound with potent and selective activity against the human immunodeficiency virus. J Biol Chem. 1992 Jan 5;267(1):257–260. [PubMed] [Google Scholar]
  7. Cihlar T., Chen M. S. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol Pharmacol. 1996 Dec;50(6):1502–1510. [PubMed] [Google Scholar]
  8. Cundy K. C., Bidgood A. M., Lynch G., Shaw J. P., Griffin L., Lee W. A. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab Dispos. 1996 Jul;24(7):745–752. [PubMed] [Google Scholar]
  9. De Clercq E., Sakuma T., Baba M., Pauwels R., Balzarini J., Rosenberg I., Holý A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 1987 Dec;8(5-6):261–272. doi: 10.1016/s0166-3542(87)80004-9. [DOI] [PubMed] [Google Scholar]
  10. Helfman D. M., Katoh N., Kuo J. F. Purification and properties of cyclic CMP phosphodiesterase. Adv Cyclic Nucleotide Protein Phosphorylation Res. 1984;16:403–416. [PubMed] [Google Scholar]
  11. Helfman D. M., Kuo J. F. A homogeneous cyclic CMP phosphodiesterase hydrolyzes both pyrimidine and purine cyclic 2':3'- and 3':5'-nucleotides. J Biol Chem. 1982 Jan 25;257(2):1044–1047. [PubMed] [Google Scholar]
  12. Helfman D. M., Kuo J. F. Differential effects of various phosphodiesterase inhibitors, pyrimidine and purine compounds, and inorganic phosphates on cyclic CMP, cyclic AMP and cyclic GMP phosphodiesterases. Biochem Pharmacol. 1982 Jan 1;31(1):43–47. doi: 10.1016/0006-2952(82)90233-7. [DOI] [PubMed] [Google Scholar]
  13. Helfman D. M., Shoji M., Kuo J. F. Purification to homogeneity and general properties of a novel phosphodiesterase hydrolyzing cyclic CMP and cyclic AMP. J Biol Chem. 1981 Jun 25;256(12):6327–6334. [PubMed] [Google Scholar]
  14. Ho H. T., Woods K. L., Bronson J. J., De Boeck H., Martin J. C., Hitchcock M. J. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol Pharmacol. 1992 Jan;41(1):197–202. [PubMed] [Google Scholar]
  15. Lalezari J. P., Drew W. L., Glutzer E., James C., Miner D., Flaherty J., Fisher P. E., Cundy K., Hannigan J., Martin J. C. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis. 1995 Apr;171(4):788–796. doi: 10.1093/infdis/171.4.788. [DOI] [PubMed] [Google Scholar]
  16. Lavan B. E., Lakey T., Houslay M. D. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form. Biochem Pharmacol. 1989 Nov 15;38(22):4123–4136. doi: 10.1016/0006-2952(89)90694-1. [DOI] [PubMed] [Google Scholar]
  17. Newton R. P. Cytidine 3',5'-cyclic monophosphate: a third cyclic nucleotide intracellular mediator? Biochem Soc Trans. 1992 May;20(2):469–474. doi: 10.1042/bst0200469. [DOI] [PubMed] [Google Scholar]
  18. Newton R. P., Salih S. G. Cyclic CMP phosphodiesterase: isolation, specificity and kinetic properties. Int J Biochem. 1986;18(8):743–752. doi: 10.1016/0020-711x(86)90398-8. [DOI] [PubMed] [Google Scholar]
  19. Polis M. A., Spooner K. M., Baird B. F., Manischewitz J. F., Jaffe H. S., Fisher P. E., Falloon J., Davey R. T., Jr, Kovacs J. A., Walker R. E. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother. 1995 Apr;39(4):882–886. doi: 10.1128/aac.39.4.882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Worby A., Mensah L. M., Murray K. J. Identification of the novel rat liver IBMX-insensitive phosphodiesterase as a non-specific phosphodiesterase capable of hydrolysing cCMP. Biochem Pharmacol. 1991 Aug 22;42(6):1318–1321. doi: 10.1016/0006-2952(91)90274-9. [DOI] [PubMed] [Google Scholar]
  21. Xiong X., Smith J. L., Kim C., Huang E. S., Chen M. S. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem Pharmacol. 1996 Jun 14;51(11):1563–1567. doi: 10.1016/0006-2952(96)00100-1. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES